PNP Therapeutics, Inc.Home About Us Contact Us Feedback Contents Search

Patents
News ] Technology Brief ] [ Patents ] Publications ] Employment ]

 

 

Title: Recombinant Bacterial Cells for Delivery of PNP to Tumor Cells
United States Patent Number 6,491,905
Date of Patent December 10, 2002
Inventors  Eric J. Sorscher, William B. Parker, William Waud, Vijayakrishna K. Gadi, Leonard L. Bennett, Jr.
Assignees  University of Alabama at Birmingham Research Foundation and Southern Research Institute

Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells.

Title: Purine Nucleoside Phosphorylase Gene Therapy for Human Malignancy

United States Patent Number

5,552,311

Date of Patent

September 3, 1996

Inventors

Eric J. Sorscher, William B. Parker, Leonard L. Bennett, Jr.

Assignees

University of Alabama at Birmingham Research Foundation and Southern Research Institute

Abstract: The invention provides a method of killing replicating or non-replicating, transfected or transduced mammalian cells and bystander cells, comprising the following steps: (a) transfecting or transducing mammalian cells with nucleic acid encoding a non-human purine nucleoside phosphorylase (PNP); and (b) contacting the transfected or transduced cells with an amount of a substrate for the purine nucleoside phosphorylase sufficient to produce a toxic purine base-analog thereby killing the transfected or transduced cells and bystander cells. In the present method of killing cells, the non-human purine nucleoside phosphorylase can be an E. coli purine nucleoside phosphorylase. The method of the invention described above can utilize a substrate that is a purine nucleoside analog. For instance, in the method provided in the Examples, the substrate is 9-(ß-D-2-deoxy-erythropentofuranosyl)-6-methlypurine (MeP-dR).

Title: Purine Nucleoside Phosphorylase Gene Therapy for Human Malignancy

United States Patent Number

6,017,896

Date of Patent

January 25, 2000

Inventors

Eric J. Sorscher, Leonard L. Bennett, Jr., William B. Parker

Assignees

University of Alabama at Birmingham Research Foundation and Southern Research Institute

Abstract: The present invention provides a method of killing replicating or non-replicating, transfected or transduced mammalian cells and bystander cells, comprising: (a) transfecting or transducing mammalian cells with nucleic acid encoding a non-human purine cleavage enzyme; and (b) contacting the transfected or transduced cells with an effective amount of a substrate for the purine cleavage enzyme, wherein the substrate is non-toxic to mammalian cells and is cleaved by the enzyme to yield a purine toxic to the targeted mammalian cells and bystander cells, to kill the mammalian cells expressing the enzyme and the bystander cells. Further provided is a vector comprising a DNA sequence coding for a non-human purine nucleoside phosphorylase protein and the vector is capable of replication and/or expression in a host which comprises, in operable linkage: a) optionally, an origin of replication: b) a promoter; and c) a DNA sequence coding for said protein.

 

Home ]

Send mail to our webmaster with questions or comments about this web site.   Legal Information.
Copyright © 2001-2008 PNP Therapeutics, Inc.    PNP Therapeutics is a Registered Trademark of PNP Therapeutics, Inc.   Web design, hosting and support by Sollicito, Inc.
Last modified: April 07, 2008